# US 2019/0315797 A1 · Abiraterone derivative and formulations thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315797 A1
- Document ID: US20190315797A1
- Status: Published application
- Kind: A1
- Application number: 16/341,206
- Filed: 2017-10-11
- Published: 2019-10-17
- Earliest claimed: 2016-10-11
- Assignees: Zhuhai Beihai Biotech Co., Ltd.
- Applicants: Zhuhai Beihai Biotech Co., Ltd.
- Inventors: Qun Sun
- Web page: https://patentgrep.com/patent/US20190315797A1

## CPC

- C07J 43/003: {not condensed}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- C07J: STEROIDS (seco-steroids C07C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This document relates to an abiraterone derivative, 2-(((3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-2-oxoacetic acid (ABOA). This document also relates to compositions comprising a non-covalently bound complex comprising ABOA and human serum albumin, wherein the ABOA and the human serum albumin in the composition have a ratio of weight from about 1:1 to about 1:2000. This document also relates to compositions comprising ABOA and human serum albumin, wherein the ABOA and the human serum albumin in the composition have a ratio of weight from about 1:1 to about 1:2000. This document also relates to compositions consisting essentially of ABOA and human serum albumin, wherein the ABOA and the human serum albumin in the composition have a ratio of weight from about 1:1 to about 1:2000.

## Claims

### Claim 1

A compound, 2-(((3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-2-oxoacetic acid (ABOA), or a pharmaceutically acceptable salt thereof, wherein the compound has the structure:

### Claim 2

A pharmaceutical composition comprising ABOA, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 3

A composition comprising a non-covalently bound complex comprising ABOA and human serum albumin, wherein the ABOA and the human serum albumin in the composition have a ratio by weight from about 1:1 to about 1:2000.

### Claim 4

A composition comprising ABOA and human serum albumin, wherein the ABOA and the human serum albumin in the composition have a ratio by weight from about 1:1 to about 1:2000.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the ABOA and the human serum albumin in the composition have a ratio by weight from about 1:20 to about 1:600.

### Claim 6 (depends on 4, 5)

The composition of any one of claims 4-5, wherein the ABOA and the human serum albumin in the composition have a ratio by weight of about 1:20, about 1:30, about 1:35, about 1:40, about 1:45, or about 1:50.

### Claim 7 (depends on 3, 4, 5, 6)

The composition of any one of claims 3-6, wherein the composition is a solid formulation.

### Claim 8 (depends on 3, 4, 5, 6)

The composition of any one of claims 3-6, wherein the composition is an aqueous formulation.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the aqueous formulation is substantially free of solvent other than water.

### Claim 10 (depends on 8, 9)

The composition of anyone of claims 8-9, wherein the aqueous formulation is a clear aqueous solution.

### Claim 11 (depends on 8, 9, 10)

The composition of any one of claims 8-10, wherein the aqueous formulation has pH value from about 5 to about 8.

### Claim 12 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11)

A pharmaceutical composition comprising the composition of any one of claims 3-11, and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

A method of treating a cancer, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 12.

### Claim 14 (depends on 13)

The method of claim 13, wherein the cancer is a metastatic castration-resistant prostate cancer.
